Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for ImmunityBio (IBRX) over the last 5 years, with Q4 2018 value amounting to $2.7 million.

  • ImmunityBio's Non-Current Deffered Revenue fell 1762.41% to $2.7 million in Q4 2018 from the same period last year, while for Dec 2018 it was $2.7 million, marking a year-over-year decrease of 1762.41%. This contributed to the annual value of $2.7 million for FY2018, which is 1762.41% down from last year.
  • Per ImmunityBio's latest filing, its Non-Current Deffered Revenue stood at $2.7 million for Q4 2018, which was down 1762.41% from $2.9 million recorded in Q3 2018.
  • In the past 5 years, ImmunityBio's Non-Current Deffered Revenue ranged from a high of $3.6 million in Q2 2017 and a low of $3000.0 during Q2 2015
  • For the 5-year period, ImmunityBio's Non-Current Deffered Revenue averaged around $2.2 million, with its median value being $2.5 million (2016).
  • As far as peak fluctuations go, ImmunityBio's Non-Current Deffered Revenue soared by 6403333.33% in 2016, and later tumbled by 1762.41% in 2018.
  • ImmunityBio's Non-Current Deffered Revenue (Quarter) stood at $521000.0 in 2014, then surged by 62.19% to $845000.0 in 2015, then soared by 187.1% to $2.4 million in 2016, then soared by 37.06% to $3.3 million in 2017, then decreased by 17.62% to $2.7 million in 2018.
  • Its Non-Current Deffered Revenue was $2.7 million in Q4 2018, compared to $2.9 million in Q3 2018 and $3.0 million in Q2 2018.